PL3443979T3 - Schemat dawkowania il-2 do leczenia tocznia rumieniowatego układowego - Google Patents
Schemat dawkowania il-2 do leczenia tocznia rumieniowatego układowegoInfo
- Publication number
- PL3443979T3 PL3443979T3 PL18179669T PL18179669T PL3443979T3 PL 3443979 T3 PL3443979 T3 PL 3443979T3 PL 18179669 T PL18179669 T PL 18179669T PL 18179669 T PL18179669 T PL 18179669T PL 3443979 T3 PL3443979 T3 PL 3443979T3
- Authority
- PL
- Poland
- Prior art keywords
- lupus erythematosus
- systemic lupus
- dosage regimen
- treating systemic
- treating
- Prior art date
Links
- 101150083678 IL2 gene Proteins 0.000 title 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451663P | 2011-03-11 | 2011-03-11 | |
| EP11305269 | 2011-03-11 | ||
| EP18179669.9A EP3443979B1 (en) | 2011-03-11 | 2012-03-09 | Il-2 dosage regimen for treating systemic lupus erythematosus |
| PCT/EP2012/054174 WO2012123381A1 (en) | 2011-03-11 | 2012-03-09 | Use of low dose il-2 for treating autoimmune - related or inflammatory disorders |
| EP12708029.9A EP2683395B1 (en) | 2011-03-11 | 2012-03-09 | Use of low dose il-2 for treating type 1 diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3443979T3 true PL3443979T3 (pl) | 2020-11-16 |
Family
ID=44244599
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18179669T PL3443979T3 (pl) | 2011-03-11 | 2012-03-09 | Schemat dawkowania il-2 do leczenia tocznia rumieniowatego układowego |
| PL12708029T PL2683395T3 (pl) | 2011-03-11 | 2012-03-09 | Zastosowanie małych dawek il-2 do leczenia cukrzycy typu 1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12708029T PL2683395T3 (pl) | 2011-03-11 | 2012-03-09 | Zastosowanie małych dawek il-2 do leczenia cukrzycy typu 1 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12491232B2 (pl) |
| EP (3) | EP2683395B1 (pl) |
| JP (2) | JP6054889B2 (pl) |
| KR (1) | KR102220006B1 (pl) |
| CN (2) | CN103732241A (pl) |
| AU (4) | AU2012228418B2 (pl) |
| DK (2) | DK2683395T3 (pl) |
| ES (1) | ES2693645T3 (pl) |
| MX (2) | MX347324B (pl) |
| PL (2) | PL3443979T3 (pl) |
| WO (1) | WO2012123381A1 (pl) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011007647A (es) | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| WO2014110258A1 (en) * | 2013-01-09 | 2014-07-17 | Podack Eckhard R | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
| WO2014206899A1 (en) * | 2013-06-25 | 2014-12-31 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Boosting treg cells for treating alzheimer disease and related disorders |
| JP6306201B2 (ja) | 2014-02-06 | 2018-04-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | インターロイキン−２融合タンパク質及びその使用 |
| EP2918285A1 (en) | 2014-03-11 | 2015-09-16 | Université Pierre et Marie Curie (Paris 6) | Interleukin-2 for treating food allergy |
| ES2746553T3 (es) * | 2014-04-22 | 2020-03-06 | Inst Nat Sante Rech Med | Métodos para el diagnóstico de una enfermedad autoinmunitaria |
| CN104189892A (zh) * | 2014-08-22 | 2014-12-10 | 北京大学人民医院 | 低剂量白细胞介素2在免疫相关性疾病治疗中的应用 |
| CN113230384A (zh) * | 2014-10-09 | 2021-08-10 | 丹娜法伯癌症研究院 | 用于治疗免疫失调的多次-可变il-2剂量方案 |
| CN104459129A (zh) * | 2015-01-05 | 2015-03-25 | 复旦大学附属华山医院 | 一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒 |
| MY188430A (en) | 2015-04-10 | 2021-12-08 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| US12023367B2 (en) | 2015-06-19 | 2024-07-02 | University Of Louisville Research Foundation, Inc. | Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection |
| JP2018526459A (ja) * | 2015-09-10 | 2018-09-13 | アシスタンス ピュブリク−オピトー ドゥ パリＡｓｓｉｓｔａｎｃｅ Ｐｕｂｌｉｑｕｅ − Ｈｏｐｉｔａｕｘ Ｄｅ Ｐａｒｉｓ | 脊椎関節症の処置のためのインターロイキン−２の使用 |
| WO2017123633A1 (en) * | 2016-01-11 | 2017-07-20 | Dignity Health | Modulators of zinc activated cation channel |
| EP3431096B1 (en) * | 2016-03-16 | 2024-12-18 | Xie, Yanhui | Glucocorticoid combined with polyethylene glycol-modified interleukin-2 for treating respiratory disease |
| KR20190129077A (ko) | 2017-03-15 | 2019-11-19 | 팬디온 테라퓨틱스, 인코포레이티드 | 표적화된 면역관용 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| WO2019096787A1 (en) * | 2017-11-14 | 2019-05-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Regulatory t cells genetically modified for the lymphotoxin alpha gene and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| SG11202011242SA (en) * | 2018-05-21 | 2020-12-30 | Nektar Therapeutics | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS |
| WO2020007937A1 (en) * | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| WO2020185624A1 (en) * | 2019-03-08 | 2020-09-17 | DrugCendR, Inc. | Low-dose cytokine co-administered with irgd for treating cancer |
| CN109999179A (zh) * | 2019-05-08 | 2019-07-12 | 山东省分析测试中心 | 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用 |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| CN110251659A (zh) * | 2019-07-03 | 2019-09-20 | 安徽省立医院 | 一种小剂量白细胞介素2在制备治疗慢性痛风药物中的应用 |
| EP4004025A1 (en) | 2019-07-26 | 2022-06-01 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| WO2021176044A1 (en) | 2020-03-06 | 2021-09-10 | Centre Hospitalier Universitaire De Nimes | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis |
| US12098178B2 (en) | 2020-12-04 | 2024-09-24 | Visterra, Inc. | Methods of using interleukin-2 agents |
| KR20230169147A (ko) * | 2021-03-11 | 2023-12-15 | 더 메서디스트 하스피틀 | 질환 치료를 위한 방법 및 조성물 |
| CN113304248B (zh) * | 2021-07-01 | 2023-01-03 | 北京大学人民医院 | Il-2在制备缓解糖皮质激素类药物副作用的药物中的应用 |
| CN115607653B (zh) * | 2022-07-09 | 2023-09-26 | 曹霞 | 低剂量白介素2在治疗孤独症中的应用 |
| CN115487292B (zh) * | 2022-09-28 | 2025-01-21 | 河北师范大学 | 一种治疗糖尿病的联合用药物及其应用 |
| EP4630035A1 (en) | 2022-12-05 | 2025-10-15 | Centre Hospitalier Universitaire de Nimes | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients |
| CN115779072B (zh) * | 2023-02-06 | 2023-10-17 | 北京大学第三医院（北京大学第三临床医学院） | 一种包含低浓度il-2的用于治疗干眼的药物组合物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341562C (en) | 1982-03-31 | 2007-11-27 | Tadatsugu Taniguchi | Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell |
| IE56026B1 (en) | 1982-10-19 | 1991-03-27 | Cetus Corp | Cysteine-depleted muteins of biologically active proteins |
| WO1985000817A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
| US4656132A (en) | 1984-03-28 | 1987-04-07 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| US4752585A (en) | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
| CA1340265C (en) | 1985-01-18 | 1998-12-15 | Kirston E. Koths | Oxidation resistant muteins |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| JPS63183538A (ja) * | 1986-09-01 | 1988-07-28 | Takeda Chem Ind Ltd | 関節リウマチまたは全身性エリテマト−デスの改善，治療剤 |
| EP0262802A3 (en) * | 1986-09-01 | 1990-01-31 | Takeda Chemical Industries, Ltd. | Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus |
| US5466447A (en) * | 1988-06-29 | 1995-11-14 | Amgen Inc. | Method for treating psoriasis |
| WO1991014444A1 (en) | 1990-03-19 | 1991-10-03 | Brigham And Women's Hospital | Treatment of cachexia with interleukin 2 |
| FR2769505B1 (fr) | 1997-10-10 | 2000-06-30 | Michael Gerard Tovey | Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations |
| GB9724838D0 (en) | 1997-11-26 | 1998-01-21 | Franks Christopher R | Compositions |
| WO2002078624A2 (en) * | 2001-03-30 | 2002-10-10 | Mayo Foundation For Medical Education And Research | Aerosol administration of interleukin-2 liposomes |
| WO2003075670A1 (en) * | 2002-03-08 | 2003-09-18 | Monsanto Technology Llc | Treatment and prevention of inflammatory disorders |
| DE60233576D1 (de) * | 2002-12-02 | 2009-10-15 | Innate Pharma | Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen |
| GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| US20070098685A1 (en) * | 2005-01-19 | 2007-05-03 | Brand Stephen J | Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist |
| MX2007009012A (es) | 2005-01-27 | 2007-09-14 | Novartis Vaccines & Diagnostic | Metodos para tratar carcinoma de celulas renales. |
| JP5604311B2 (ja) | 2008-03-13 | 2014-10-08 | バイオテスト・アクチエンゲゼルシヤフト | 疾患治療剤 |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| WO2010049438A2 (en) | 2008-10-30 | 2010-05-06 | Innate Pharma | Improved methods of using phosphoantigens for the treatment of diseases |
| MX2011007647A (es) | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
| CN102462837B (zh) | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
| BR112013023151A2 (pt) * | 2011-03-11 | 2020-09-15 | Assistance Publique - Hôpitaux De Paris | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado |
-
2012
- 2012-03-09 PL PL18179669T patent/PL3443979T3/pl unknown
- 2012-03-09 EP EP12708029.9A patent/EP2683395B1/en active Active
- 2012-03-09 AU AU2012228418A patent/AU2012228418B2/en active Active
- 2012-03-09 EP EP18179669.9A patent/EP3443979B1/en active Active
- 2012-03-09 PL PL12708029T patent/PL2683395T3/pl unknown
- 2012-03-09 DK DK12708029.9T patent/DK2683395T3/en active
- 2012-03-09 KR KR1020137026950A patent/KR102220006B1/ko active Active
- 2012-03-09 ES ES12708029.9T patent/ES2693645T3/es active Active
- 2012-03-09 JP JP2013557125A patent/JP6054889B2/ja active Active
- 2012-03-09 EP EP20175639.2A patent/EP3766513A1/en active Pending
- 2012-03-09 CN CN201280012853.6A patent/CN103732241A/zh active Pending
- 2012-03-09 MX MX2013010342A patent/MX347324B/es active IP Right Grant
- 2012-03-09 MX MX2017004594A patent/MX384095B/es unknown
- 2012-03-09 WO PCT/EP2012/054174 patent/WO2012123381A1/en not_active Ceased
- 2012-03-09 DK DK18179669.9T patent/DK3443979T3/da active
- 2012-03-09 CN CN201810358897.3A patent/CN109432407A/zh active Pending
-
2016
- 2016-12-13 AU AU2016273847A patent/AU2016273847B2/en active Active
-
2018
- 2018-07-17 AU AU2018206705A patent/AU2018206705B2/en active Active
-
2020
- 2020-06-17 AU AU2020204023A patent/AU2020204023B2/en active Active
-
2023
- 2023-01-06 US US18/151,383 patent/US12491232B2/en active Active
- 2023-01-11 JP JP2023002251A patent/JP7561893B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3443979T3 (pl) | Schemat dawkowania il-2 do leczenia tocznia rumieniowatego układowego | |
| PL2838594T3 (pl) | Urządzenie do inhalacji substancji w postaci proszku | |
| IL273076A (en) | Solid dosage form | |
| PL2914386T3 (pl) | Urządzenie do sortowania | |
| EP2677902A4 (en) | PLATEAU DEVICE | |
| SG11201402161YA (en) | Conveying device for leads | |
| PL2904124T3 (pl) | Urządzenie manipulacyjne | |
| PL2574421T3 (pl) | Urządzenie obróbcze | |
| PL2752161T3 (pl) | Urządzenie prowadzące | |
| GB2549901B (en) | Devices for Blending Materials | |
| EP2865919A4 (en) | DEVICE FOR DAMPING VIBRATIONS | |
| PT2867538T (pt) | Bomba ou compressor com dispositivo antirredemoinho e método associado | |
| TWI562685B (en) | Plasma processing device | |
| SG11201500389UA (en) | Device for treating an object with plasma | |
| GB2491611B (en) | Dose indicator device | |
| EP2687690A4 (en) | DEVICE FOR TREATING PARTICULATE MATTER | |
| GB2507712B (en) | Charging device | |
| AU345907S (en) | Conduit tray | |
| TWI561335B (en) | Positioning device for lathe | |
| GB2495616B (en) | Charging device | |
| SI2620345T1 (sl) | Naprava za drsenje vzdolž kablov | |
| ZA201502265B (en) | Apparatus for document handling | |
| PL2892641T3 (pl) | Urządzenie napełniające do katalizatorów | |
| EP2837595A4 (en) | DEVICE FOR FUEL PROCESSING | |
| EP2766506A4 (en) | PLASMA PROCESSING DEVICE |